Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus premixed insulin for carotid intima-media thickness in type 2 diabetes
ChiCTR1800015658Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Nov 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exenatide and Insulin aspart + insulin aspart protamine in type 2 diabetes mellitus (T2DM) and atherosclerosis (2 arms), sponsored by Beijing Hospital. Primary endpoint: carotid intima-media thickness. Started Nov 2015; status: recruiting.
02
Drugs
exenatideInsulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on ChiCTR1800015658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015658.